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Abstract
Urea cycle converts ammonia, a waste product of protein catabolism and a 
neurotoxin, into non-toxic urea. Urea cycle disorders are a group of rare genetic dis-
eases that have protein-restricted diet as a common treatment modality. Expression 
of urea cycle genes is regulated in concert by the dietary protein intake, but the 
mechanism of this regulation is not well understood. Data mining of databases such 
as ENCODE and Cistrome can be used to gain new information about regulatory 
elements, transcription factors, and epigenetic mechanisms that regulate expres-
sion of urea cycle genes. This can lead to better understanding of the common 
mechanism, which regulates urea cycle genes, and can generate testable hypotheses 
about regulation of gene expression and new treatments for urea cycle disorders.
Keywords: urea cycle, transcriptional regulation, transcription factor, data mining, 
ChIP-Seq, epigenetic, histone modification, chromatin remodeler
1. Introduction
Transcriptional regulation of gene expression is essential for development, 
tissue differentiation, and organisms’ responses to changes in their environment. 
Maintenance of homeostasis would be impossible without regulation of expression 
of genes that code for enzymes in the carbohydrate, fat, and protein metabolism. 
Omnivorous mammals, such as humans, mice, and rats, can adapt their metabo-
lism to varying proportions of amino acids, fats, and carbohydrates as sources of 
energy [1, 2]. Strict carnivores, such as cats, lack such adaptive mechanisms [3]. 
Diet rich in carbohydrates and fats triggers utilization of these nutrients as sources 
of energy and storage of excess sugars and fat in the form of glycogen and adipose 
tissue [1, 4]. On the other hand, a diet rich in proteins imposes changes in nitrogen 
balance because excess proteins and amino acids cannot be stored [1]. High intake 
of proteins, combined with low intake of carbohydrates and fats, leads to utilization 
of amino acids as energy sources and results in increased catabolism of amino acids 
[1, 4] and increased need to dispose of waste nitrogen, generated in this process. 
Transcriptional regulation of expression of enzymes in the pathways for degrada-
tion of nutrients as well as biosynthesis of molecules that can be stored is necessary 
for adaptations to these dietary changes.
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Urea cycle is a liver metabolic pathway that converts ammonia into urea. 
Ammonia is a waste product of catabolism of dietary and cellular proteins, and a 
potent neurotoxin [5]. Defects in any of the enzymes of the urea cycle lead to partial 
or complete block of urea production and accumulation of ammonia, which dam-
ages the brain and can be lethal [5]. Therefore, the physiological role of urea cycle is 
to protect the brain from the toxic effects of ammonia.
Five enzymes of the urea cycle, carbamoyl phosphate synthetase 1 (CPS1), 
ornithine transcarbamylase (OTC), argininosuccinate synthase (ASS), arginino-
succinate lyase (ASL) and arginase 1, catalyze conversion of ammonia into urea. 
In addition, N-acetylglutamate synthase (NAGS), ornithine/citrulline transporter 
(ORNT), and aspartate/glutamate transporter (also known as ARALAR2 or Citrin) 
are required for the normal function of the urea cycle. The pathway is partitioned 
between mitochondria and cytoplasm of the liver cells. NAGS, CPS1, and OTC are 
located in the mitochondrial matrix [6] while ASS, ASL, and arginase 1 are in the 
cytosol [6]. Figure 1 shows enzymes, transporters, and intermediates of the urea 
cycle together with their cellular localization. The NAGS (EC 2.3.1.1) uses gluta-
mate and acetyl coenzyme A to produce NAG, an obligatory allosteric activator of 
CPS1 [6–9]. Upon binding of NAGS, CPS1 (EC 6.3.4.16) consumes two molecules 
of ATP to catalyze formation of carbamoyl phosphate from ammonia and bicar-
bonate [6, 10]. Carbamoyl phosphate and ornithine, which is transported into 
mitochondria by ORNT, are converted to citrulline by OTC (EC 2.1.3.3), followed 
by the transport of citrulline from mitochondria into cytoplasm by ORNT [6]. ASS 
(EC 6.3.4.5) catalyzes formation of argininosuccinate from citrulline and aspar-
tate, which is supplied by the Citrin [6]. The argininosuccinate is then converted 
Figure 1. 
Enzymes, transporters, and intermediates of the urea cycle. Urea cycle enzymes are shown in blue typeface: 
NAGS—N-acetylglutamate synthase, CPS1—carbamoyl phosphate synthetase 1, OTC—ornithine 
transcarbamylase, ASS—argininosuccinate synthase, ASL—argininosuccinate lyase, and Arg1—arginase 1. 
Urea cycle transporters ORNT (ornithine/citrulline transporter) and Citrin (glutamate/aspartate transporter) 
are shown as ovals. The orange arrow indicates activation of CPS1 by N-acetylglutamate (NAG). AcCoA—
acetyl coenzyme A. CoASH—coenzyme A.
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to arginine by the ASL (EC 4.3.2.1). Arginase 1 (EC 3.5.3.1) completes the cycle by 
hydrolyzing arginine into urea and ornithine, which is transported into mitochon-
dria to be a substrate for OTC (Figure 1). Urea cycle genes and enzymes are not 
uniformly expressed in the liver; their expression follows a gradient from high in 
hepatocytes surrounding portal vein to no expression in hepatocytes surrounding 
central vein [11]. NAGS, CPSI, and OTC are also expressed in the small intestine, 
where they synthesize citrulline which is then transported to the kidneys for the 
biosynthesis of arginine by the ASS and ASL [6]. Argininosuccinate synthase and 
lyase also function in the NO signaling and are present in the tissues that express 
nitrous oxide synthase [5].
Long-term changes in dietary protein intake lead to adaptive changes in expres-
sion of urea cycle enzymes. Their expression increases in rats and monkeys fed 
high-protein diet and decreases upon feeding of low-protein diet [4, 12]. These 
adaptive changes seem to be mediated, at least in part, by the hormones glucagon, 
glucocorticoid, and insulin [13–25]. Glucagon and glucocorticoid hormones trig-
ger changes in mRNA and protein levels of all five urea cycle enzymes, but the 
mechanisms responsible for these changes seem to differ for each enzyme [21]. It 
is not known whether changes in the dietary protein intake trigger similar changes 
in the expression of the NAGS gene because it has not been identified at the time. 
Also unknown are signaling cascades that mediate effects of hormones to regulate 
expression of urea cycle genes and whether specific amino acids and/or other 
metabolites act as sensors of the dietary protein intake.
Inspection of the regulatory regions of genes for urea cycle enzymes (Figure 2) 
does not reveal a common regulatory element that would bind one or more transcrip-
tional factors to coordinately regulate transcription of all urea cycle genes [13, 26–36]. 
The studies of expression of urea cycle genes in knockout mice also show a lack of 
common regulatory mechanism. Ureagenesis is defective in mice lacking hepatocyte 
nuclear factor 4 α (HNF4α) due to absence of OTC mRNA and protein [37] as well 
as in mice lacking CCAAT/enhancer binding protein α (C/EBPα) due to lack of CPSI 
mRNA [38]. However, ureagenesis appears normal in mice lacking C/EBPβ although 
this transcriptional factor appears to regulate expression of the arginase 1 gene [39]. It 
is also unknown if short-term increases in nitrogen load following a meal trigger any 
change in expression of urea cycle enzymes.
This chapter focuses on the regulation of NAGS, CPS1, and OTC expression 
because their only known functions are protection of the brain from ammonia 
toxicity through participation in the urea cycle and intestinal biosynthesis of citrul-
line. The three genes share common expression pattern in the liver, intestine, and 
during development. Because of the role of urea cycle in protecting the brain from 
ammonia toxicity, expression of the three genes have been studied in much greater 
detail in the liver than intestinal cells. Detailed understanding of the transcriptional 
regulation of the urea cycle genes is important for our understanding of bodies’ 
response to changes in the environment such as dietary changes as well as events 
that trigger increased catabolism of cellular proteins such as starvation, infections, 
and invasive medical procedures [6, 40–43]. Because regulation of expression of 
the mammalian CPS1 and OTC genes has been studied for more than three decades 
while expression of human NAGS, which was identified and cloned in 2002, took 
place less than a decade ago the approaches taken in these studies differed greatly. 
Knowledge of transcriptional regulation of mammalian CPS1 and OTC was gained 
through cloning of genomic DNA, construction of reporter gene plasmids with 
various fragments from the CPS1 and OTC regulatory regions and their expression 
in cultured cells and transgenic mice, whereas regulatory elements of the NAGS 
gene have been identified using comparative genomics approaches.
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2. Transcriptional regulation of urea cycle genes
2.1 Transcriptional regulation of mammalian NAGS gene
Although the existence of mammalian NAGS gene and its product have been 
known since the 1950s [44], the gene remained elusive until 2002, when it was 
identified and cloned in mice and humans [45–48]. The human NAGS gene is 
located on chromosome 17 within band 17q21.31 and spans approximately 8.5 kb. 
This includes seven exons that encode a 1605 bp open reading frame, six introns, a 
promoter, and an enhancer located about 3 kb upstream of the transcription start 
sites [45, 47, 49–51]. The mouse Nags gene is located in the syntenic region on chro-
mosome 11. Pairwise BLAST [52] was used for comparison of the regions upstream 
of the NAGS genes from seven mammals including human; this analysis revealed 
two conserved elements, one located immediately upstream of the first exon of 
Figure 2. 
Transcriptional regulatory elements of the urea cycle genes. Hooked arrows indicate transcriptional initiation 
sites. Gray boxes—cisacting regulatory elements. Proteins that bind to cis-acting regulatory elements are shown 
above each box. C/EBP—CCAAT/enhancer binding proteins; HNF4α—hepatic nuclear factor a; COUP-TF—
chicken ovalbumin upstream promoter transcriptional factor; FoxA—forkhead box A transcriptional factor/
hepatic nuclear factor 3; GR—glucocorticoid receptor; P3—unidentified protein of approx. 75 kDa; P1, 
P2—two unidentified proteins; NF-Y—CCAAT—binding factor; AP-2—activator protein 2; Sp1—Sp1 
transcriptional factor; CREB—cAMP response element binding transcription factor.
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the NAGS gene and a putative regulatory element located about 3 kb upstream of 
the NAGS translation initiation site [50]. The pattern of DNA sequence conserva-
tion within the conserved region immediately upstream of the first exon of the 
NAGS gene suggested that it might consist of a promoter and a proximal regulatory 
element, which is similar to the CPS1 regulatory region that will be described in the 
next section. Cis-element over-representation (CLOVER) software [53] was then 
used to identify binding sites for specificity protein 1 (Sp1), cAMP response ele-
ment binding/activating transcription factor (CREB/ATF), and CCAAT-enhancer 
binding protein (C/EBP) transcription factors in the putative NAGS promoter, 
while activator protein-2 (AP2), hepatic nuclear factor 1 (HNF1), nuclear factor-Y 
(NF-Y), and mothers against decapentaplegic homolog 3 (SMAD3) binding sites 
were found in the upstream regulatory element, which was named −3 kb enhancer. 
These findings were then experimentally verified.
Reporter gene assays were used to confirm that conserved regions located adja-
cent to and −3 kb upstream of the first NAGS exon indeed function as a promoter 
and enhancer in the HepG2 hepatoma cells [50]. Consistent with the absence of the 
TATA-box in the NAGS promoter, transcription of the NAGS mRNA in the liver and 
intestine initiates at multiple sites located between 50 and 150 bp upstream of the 
NAGS translation initiation codon [50]. Binding of the Sp1 and CREB transcription 
factors to the NAGS promoter, and binding of the HNF1 and NF-Y transcription 
factors to the −3 kb enhancer were confirmed with chromatin immunoprecipita-
tion (ChIP) and DNA pull-down assays [50]. Binding of HNF1 to the −3 kb NAGS 
enhancer is responsible for the liver-specific expression of the NAGS gene [50] and 
the role of HNF1 transcription factor in expression of the NAGS gene was con-
firmed when a sequence variant that caused decreased HNF1 binding to its site was 
found in a patient with NAGS deficiency [49].
2.2 Transcriptional regulation of mammalian CPS1 gene
Regulatory region of the rat Cps1 gene has been cloned in 1985 [54]. Almost all 
of our knowledge of transcriptional regulation of the CPS1 gene is based on experi-
ments with the rat Cps1 gene in the rat and human hepatoma cell lines and trans-
genic mice. The aim of these studies was to elucidate the mechanism of regulation 
of Cps1 expression by glucagon and glucocorticoids as well as identify regulatory 
elements that restrict Cps1 expression to periportal hepatocytes [55–57].
A promoter, located immediately upstream of the first Cps1 exon, a proximal 
enhancer that is immediately adjacent to the promoter, a distal enhancer located 
about 6 kb upstream of the Cps1 translation initiation codon, and another regula-
tory element located about 10 kb upstream of the Cps1 translation initiation site 
are responsible for transcriptional regulation of the rat Cps1 gene [27, 29, 56, 58]. 
Transcription of the rat Cps1 mRNA is initiated 138–140 bp upstream of the transla-
tion initiation site by the promoter that has TATA and CAAT motifs [59] and binds 
C/EBP transcription factor [29]. The distal Cps1 enhancer consists of a cAMP 
response unit (CRU) and a glucocorticoid response unit (GRU); each response unit 
binds multiple transcription factors that activate Cps1 expression in response to 
glucagon and glucocorticoids, and are responsible for Cps1 expression in periportal 
hepatocytes [26, 55, 56, 60]. The CRU binds CREB, HNF3, C/EBP transcription 
factors, and a yet to be identified protein P1 [60, 61], while GRU binds glucocorti-
coid receptor, hepatocyte nuclear factor 3/forkhead box A (HNF3/FOXA), C/EBP, a 
75 kDa protein P3, and a yet to be identified protein P2 [26, 61, 62]. The distal Cps1 
enhancer activates Cps1 transcription via proximal enhancer that binds C/EBP and 
glucocorticoid receptor and is located immediately upstream of the Cps1 promoter 
[63]. These studies of the rat Cps1 gene regulation rest on the premise that the rat 
Gene Expression and Control
6
gene is a good model for human CPS1. However, the two species have different 
metabolic rates due to their different sizes and regulation of the CPS1 gene and urea 
cycle may differ in the two organisms. More recently, a region of the human CPS1 
gene that corresponds to the rat Cps1 promoter and proximal enhancer has been 
shown to bind HNF3 and direct reporter gene expression in hepatoma cells [64]. 
Human CPS1 gene is located on chromosome 2, band 2q34 where it spans approx. 
125 kb and has 38 exons that encode a 1500 amino acids long protein.
2.3 Transcriptional regulation of mammalian OTC gene
The human OTC gene is 70 kb long and has 10 exons which contain a 1062 bp 
long coding sequence [65]. Transcription of the human OTC gene initiates at 
multiple transcription start sites (TSS) [66], while transcription of the mouse 
and rat Otc genes initiate at a single transcription start site located 136 and 98 bp 
upstream of the translation initiation codon [67, 68]. Within the rat Otc promoter, 
four regions, A–D, bind transcription factors that regulate expression of the Otc 
gene [31]. Region A is a negative regulator of Otc transcription [31], and transcrip-
tion factors that bind to this region have not been identified. Regions B and C bind 
transcriptional activator HNF4, and transcriptional repressor chicken ovalbumin 
upstream promoter—transcription factor (COUP-TF) [30, 31]. Region D is located 
downstream of the transcription start site and its role in expression of the Otc gene 
remains to be elucidated [31].
The rat Otc promoter is sufficient for expression of transgenes in the liver and 
intestine of transgenic mice [69, 70]. An enhancer located approximately 11 kb 
upstream of the first exon of the rat Otc gene is responsible for a high level of 
expression of the Otc gene in the liver [31]. This −11 kb enhancer has four transcrip-
tion factor-binding sites, designated I–IV [31]; sites I and II bind C/EBPβ, while 
transcription factor HNF4 binds to sites I and IV in the rat Otc enhancer to activate 
expression of the Otc gene [32, 37, 38]. Since comparative genomics studies revealed 
that the distance between regions that correspond to the −11 kb rat Otc enhancer 
and OTC promoter vary in mammalian genomes, this region was renamed as the 
liver-specific enhancer (LSE) [71].
2.4 Transcriptional regulation of the NAGS, CPS1, and OTC genes in the 
genomics era
Advances in sequencing technology-enabled sequencing of dozens of mam-
malian genomes and comparisons of their sequences revealed conserved regions 
in non-coding regions that could function as regulatory elements [72, 73]. This 
strategy was used to identify NAGS promoter and enhancer [50]. Next-generation 
sequencing also enabled examination of the function of non-coding regions in the 
human and mouse genomes including their chromatin structure, and binding of 
transcription and chromatin remodeling proteins to generate an Encyclopedia of 
Non-coding DNA Elements (ENCODE). These studies were first carried out in the 
limited number of cultured cell lines, but are now expanding to include tissues and 
cultured primary cells and their results have been stored in the ENCODE database 
[74, 75]. In addition to these large-scale projects, many individual labs have been 
performing ChIP-Seq experiments and the publically available results of their 
experiments are being gathered in the Cistrome database [76]. The advantage of 
the Cistrome database is ability to compare chromatin states and track changes in 
binding of transcription factors in response to signaling molecules, treatments, 
and environmental stimuli. Data mining of the ENCODE and Cistrome databases 
present an opportunity to identify novel regulatory elements in the NAGS, CPS1, 
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and OTC genes and transcription factors that bind to the regulatory elements. Both 
databases were queried for chromatin modifications and binding of transcription 
factors to the NAGS, CPS1, and OTC genes and their flanking regions in the liver 
tissue using following coordinates of the GRCh38/hg38 human genome assembly: 
chr17:43,994,682-44,012,832 for the NAGS gene, chr2:210,499,833-210,691,279 
for the CPS1 gene, and chrX:38,334,777-38,459,529 for the OTC gene. The follow-
ing filters were applied to experimental matrix of the ENCODE database (www.
encodeproject.org): organism—Homo sapiens, biosample type—tissue, organ—
liver, project—ENCODE, genome assembly—GRCh38, assay category—ChIP-Seq, 
assay category—DNA binding, and target of assay—transcription factor, histone, 
broad and narrow histone mark, and chromatin remodeler. Results of the query 
were visualized using UCSC Genome Browser. Results of the ChIP-Seq experiments 
for the genomic region of interest can be downloaded as either wiggle or bed files 
using Tools and Table Browser menus of the UCSC Genome Browser. The ChIP-Seq 
data for each DNA binding protein and histone modification of interest can be 
acquired by selecting ENCODE Hub from the group menu, ENCODE ChIP-Seq 
from the track menu and experiment ID from the table menu of the Table Browser 
page. Cistrome Data Browser was used to query Cistrome database (www.cistrome.
org); Homo sapiens was selected as species and hepatocyte as biological source. 
Experimental results that passed quality controls were visualized in the UCSC 
Genome Browser and results of experiments were obtained is the same way as for 
the ENCODE database.
The 5′-ends of each region were chosen based on the presence of RAD21, a 
component of cohesion, and CTCF binding that can indicate boundaries of chro-
matin domains, whereas the 3′-ends of the NAGS and OTC genomic region have 
been chosen to be either within or close to their downstream neighboring genes; 
the 3′-end of the CPS1 genomic region was chosen to include a conserved region 
downstream of the last exon of the CPS1 gene (Figures 3A, 4A, and 5A). RAD21 
and CTCF bind to additional sites within NAGS, CPS1, and OTC genes and the 
role of cohesion and CTCF in expression of the three genes is yet to be determined 
(Figures 3A, 4A, and 5A).
The H3K4me3 histone 3 modifications that mark active promoters and H3K27ac 
modifications that mark active enhancers are present at upstream regions of all 
three genes (Figures 3B, 4B, and 5B). The ENCODE database also has the DNaseI 
sensitivity data from the human fetal liver tissue that show open chromatin state 
for the NAGS gene and closed chromatin for the CPS1 and OTC genes (Figures 3B, 
4B, and 5B). This difference could be due to presence of the ubiquitously expressed 
TMEM101 gene downstream of the NAGS gene (Figure 3).
Query of the ChIP-Seq data in the ENCODE database confirmed binding of the 
Sp1, CREB/ATF3, HNF4A, HNF3/FOXA1, HNF3/FOXA2, and COUP-TF to the pro-
moters and enhancers of the NAGS, CPS1, and OTC genes and identified binding 
of these and several other transcription factors to previously identified as well as 
novel regulatory elements (Figures 3C, 4C, and 5C). Transcription factors RXRA, 
COUP-TF and HNF4A, YY1 and JUND/AP1 also appear to bind NAGS promoter 
while RXRA, HNF4A, YY1, and REST bind the −3 kb NAGS enhancer (Figure 3C).  
The ChIP-Seq data also show binding of transcription factor to regions of the 
NAGS gene that could be novel regulatory elements. For example, Sp1, RXRA, and 
HNF4A bind to a region in the first intron of the NAGS gene. ChIP-Seq data also 
show that transcription factors bind to a region located between NAGS promoter 
and −3 kb enhancer as well as to the two regions upstream of the −3 kb enhancer; 
these sites could be novel regulatory elements of the NAGS gene (Figure 3C). The 
map of the NAGS genomic region shows that transcription of the PYY gene initiates 
at the NAGS promoter but in the opposite direction (Figure 3D). This is because a 
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PYY cDNA (GenBank ID BC041057.1) has been isolated from a brain astrocytoma 
sample and sequenced [77]. This PYY transcript may have resulted from aberrant 
expression of the PYY gene in the brain astrocytoma cells since PYY is not expressed 
in the brain according to the Human Protein Atlas [78] and the GTEx track of the 
UCSC Genome Browser [79].
Transcription factors HNF3/FOXA1, HNF3/FOXA2, and CREB bind to the 
human CPS1 promoter and the region upstream of the human CPS1 that cor-
responds to the rat Cps1 distal enhancer as well as additional sites located within 
the first intron of the CPS1 gene and upstream of the distal enhancer (Figure 4C). 
Moreover, HNF4A, RXRA, SP1, YY1, JUND/AP2, and REST also bind to the CPS1 
Figure 3. 
Overview of the NAGS genomic region. (A) Binding sites for chromatin remodeling proteins. (B) Epigenetic 
marks. (C) Transcription factor binding sites. (D) Map and sequence conservation of the NAGS genomic 
region.
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upstream region and first intron (Figure 4C). It is possible that yet to be identified 
proteins P1, P2, and P3 that bind to the rat Cps1 distal enhancer are among these 
transcription factors. Likewise, the HNF4A and COUP-TF transcription factors 
that are known to bind to the OTC promoter and LSE also bind to sites upstream of 
the LSE and within first OTC intron, and additional transcription factors bind to 
these regions (Figure 5C). The novel regulatory elements that have been identified 
by the binding of transcription factors coincide with regions that are conserved in 
vertebrates as indicated by the phyloP and phastCons tracks of the UCSC Genome 
Browser (Figures 3D, 4D, and 5D).
These data mining efforts identified a common set of transcription factors that 
bind to the regulatory regions of the NAGS, CPS1, and OTC genes in the liver and 
may be responsible for the coordinated changes in their expression in response to 
dietary protein intake and hormonal signaling. The knowledge of transcription 
Figure 4. 
Overview of the CPS1 genomic region. (A) Binding sites for chromatin remodeling proteins. (B) Epigenetic 
marks. (C) Transcription factor binding sites. (D) Map and sequence conservation of the CPS1 genomic region.
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factors that regulate expression of urea cycle genes could provide a clue about 
amino acid(s) and metabolites that act as sensors of the dietary protein intake. 
Data mining of the ENCODE and Cistrome databases presented here revealed 
that transcription factor RXRA binds to regulatory elements of NAGS, CPS1, and 
OTC genes. The RXRA transcription factor regulates gene expression by forming 
heterodimers with several transcription factors including peroxisome proliferator-
activated receptor gamma (PPARγ), which regulated glucose metabolism [80]. If 
future studies show that PPARγ-RXRA heterodimer regulates expression of the 
NAGS, CPS1, and OTC genes, that would suggest that glucose, rather than amino 
acid(s), might be a sensor of the balance of protein and carbohydrate intake that 
regulates expression of the urea cycle genes. Although similar data sets are not yet 
available for the human small intestine cells, the ENCODE project is ongoing and 
future data mining efforts will provide a more complete information about tran-
scriptional regulation of the NAGS, CPS1, and OTC genes. Similarly, the Cistrome 
Figure 5. 
Overview of the OTC genomic region. (A) Binding sites for chromatin remodeling proteins. (B) Epigenetic 
marks. (C) Transcription factor binding sites. (D) Map and sequence conservation of the OTC genomic region.
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database is growing and queries of its data may reveal molecular mechanisms of 
NAGS, CPS1, and OTC regulation through differential binding of transcription 
factors to their regulatory elements. The utility of the data mining approach goes 
beyond understanding of transcriptional regulation of genes. This approach can 
be used to explain deleterious effects of sequence variants on expression of genes 
that are associated with human diseases and identify drug targets for treatment 
of diseases that can benefit from increased expression of hypomorphic alleles. In 
the case of NAGS, CPS1, or OTC deficiencies, which have high plasma ammonia, 
or hyperammonemia, as a common symptom, partial defects in any of the three 
genes result in the decreased activity or abundance of the corresponding enzyme 
and decreased capacity for ureagenesis. Protein-restricted diet, which minimizes 
ammonia production, is standard therapy for patients with partial defects of the 
NAGS, CPS1, OTC, and other urea cycle genes that were not discussed in this chap-
ter. However, protein-restricted diet also leads to decreased expression of urea cycle 
genes, including the defective one, leading to further decrease patient’s capacity for 
ureagenesis and increased risk of hyperammonemia. A drug therapy that is based 
on transcriptional regulation of the NAGS, CPS1, and OTC genes might be able to 
increase their expression even when patients are on the protein-restricted diet and 
decrease patients’ risk of hyperammonemia-induced brain damage.
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